Abstract
Proteins are ultimately responsible for cellular phenotypes and are targeted by most anticancer drugs. However, beyond immunohistochemistry, proteins are not typically measured in precision oncology, meaning transcriptomics is used as a proxy. To determine how informative mRNA is for guiding personalised treatments, mRNA-protein correlations were analysed in three large pan-cancer datasets and made available in a web portal ( https://oncorr.aws.procan.org.au/ ). OnCorr can be integrated into precision medicine programs to augment transcriptomics.